MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...

Background Aortic stenosis (AS) frequently coexists with heart failure (HF), but its prevalence, prognostic impact and management across the full HF spectrum remain incompletely characterised. Methods ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...

aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...

Waseem is a writer here at GameRant. He can still feel the pain of Harry Du Bois in Disco Elysium, the confusion of Alan Wake in the Remedy Connected Universe, the force of Ken's shoryukens and the ...

Papillary muscle scarring in DCM patients is associated with higher risks of cardiac death, heart failure, and arrhythmia events. Microvascular dysfunction is a strong predictor of poor prognosis, ...

A new major trial shows that beta-blockers don't provide any real benefit to people with the most common form of heart attack. Reading time 3 minutes A common treatment given after heart attacks may ...

MADRID -- Beta-blockers may be relegated to a smaller role for secondary prevention after myocardial infarction (MI) in contemporary practice, based on the arrival of three new trials from Europe.